Drug intelligence / Profile preview

MK-5823

Development stage: Discontinued
Lead developer: Merck
Modality: Small Molecules

Overview

MK-5823 is an investigational small molecule drug developed by Merck Sharp & Dohme (Merck) that acts as a dual agonist of the glucagon receptor (GCGR) and the glucagon-like peptide 1 receptor (GLP-1R). It was designed for the treatment of metabolic diseases, specifically type 2 diabetes mellitus and obesity. The drug entered phase 1 clinical trials to evaluate its safety, tolerability, pharmacokinetics, and pharmacodynamics in overweight/obese individuals who were either healthy or had type 2 diabetes. Development was discontinued after phase 1[1][2][6].

Targets

GCGR (Glucagon receptor)GLP1R (GLP-1R)

Beyond the preview

Go deeper on MK-5823.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MK-5823.

Explore the full profile